Tag: antimicrobial resistance

The therapy offers a promising new approach to tackling the growing challenge of antimicrobial resistance, said the study published in the international UK medical journal The Lancet Infectious Diseases in late September.

China: New Drug Used to Treat Common Infection! (19.11.2025)

A new treatment combination for Helicobacter pylori — a common stomach bacterium linked to ulcers and gastritis — based on a domestically developed drug has shown comparable, and in some cases superior, efficacy in eradicating the infection compared with standard therapy, according to recent clinical research.

The therapy offers a promising new approach to tackling the growing challenge of antimicrobial resistance, said the study published in the international journal The Lancet Infectious Diseases in late September.

The experimental triple therapy centres on rifasutenizol, a novel antimicrobial agent developed specifically for H. pylori infection by Tennor Therapeutics, a pharmaceutical company based in Suzhou, Jiangsu province.

Continue reading

Superbug - Linked to Rifaximin!

Australia: Research Confirms Common Antibiotic [Rifaximin] Linked to Rise of Dangerous Superbug! (24.10.2024)

Glen Carter, senior author of the study from the University of Melbourne and the Doherty Institute, said the study challenges the previously-held belief that rifaximin is low-risk for causing AMR.

“We’ve shown that rifaximin makes VRE resistant to daptomycin in a way that has not been seen before,” he said in a media release.

“It is also of concern that these daptomycin-resistant VRE might be transmitted to other patients in the hospital; a hypothesis that we are presently investigating.”

The authors of the new study said the findings highlight the critical need for effective genomics-based surveillance to detect emerging AMR.

Continue reading